{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-22-000146","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.213355+00:00","generated_at":"2026-06-21T07:30:45.483261+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Evolus extends $50M undrawn tranche availability to Dec 2023","bullets":["Second $50M tranche under $125M term loan facility now available until Dec 31, 2023 (extended from Dec 31, 2022).","Paid $500K amendment fee; all other terms unchanged (3-month LIBOR +8.5%, interest-only first 36 months).","First $75M tranche fully drawn in 2021; company expects existing cash to fund operations through breakeven.","CEO cites market share gains and millennial demographic focus; Pharmakon continues to support the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-22-000146","json":"https://secwatch.observer/filing/0001570562-22-000146.json","markdown":"https://secwatch.observer/filing/0001570562-22-000146.md","text":"https://secwatch.observer/filing/0001570562-22-000146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000146/0001570562-22-000146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000146/eols-20221205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:30:45.483261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a872d087a82f8c2e4ea93843d82874ce8671dd06","claim":"Evolus, Inc. amended term loan with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP.","evidence_excerpt":"On December 5, 2022, Evolus, Inc. (the “Company”) entered into a Second Amendment to Loan Agreement (the “Second Amendment”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender” and, together with BPCR Limited Partnership, the “Lenders”), and Biopharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent), which amends certain terms of the Loan and Security Agreement, dated December 14, 2021, as amended, by and among the Company, Lenders, and Collateral Agent (the “Loan Agreement”). The Second Amendment extends the Company’s option to draw down the second tranche of $50 million of the term loan facility provided under the Loan Agreement until December 31, 2023 (the “Draw Period”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000146/0001570562-22-000146-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Counterparty","value":"BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"23e2f2e21ba81e12e60b1a74e992d2a91e99b1f1","claim":"Evolus, Inc. amended Second Amendment to Loan Agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC valued at $50 million (effective 2022-12-05).","evidence_excerpt":"On December 5, 2022, Evolus, Inc. (the “Company”) entered into a Second Amendment to Loan Agreement (the “Second Amendment”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender” and, together with BPCR Limited Partnership, the “Lenders”), and Biopharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent), which amends certain terms of the Loan and Security Agreement, dated December 14, 2021, as amended, by and among the Company, Lenders, and Collateral Agent (the “Loan Agreement”). The Second Amendment extends the Company’s option to draw down the second tranche of $50 million of the term loan facility provided under the Loan Agreement until December 31, 2023 (the “Draw Period”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000146/0001570562-22-000146-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC"},{"label":"Value","value":"$50 million"},{"label":"Effective","value":"2022-12-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}